Asymmetric dimethylarginine level in hyperglycemic gestation

Basit Öğe Kaydı
dc.authoridbay karabulut, aysun/0000-0002-7873-2805
dc.authoridTURKCUOGLU, ILGIN/0000-0002-8342-1956
dc.authorwosidbay karabulut, aysun/HJP-0995-2023
dc.contributor.authorSertkaya, Ayse Cikim
dc.contributor.authorKafkasli, Ayse
dc.contributor.authorTurkcuoglu, Ilgin
dc.contributor.authorKarabulut, Aysun Bay
dc.date.accessioned2024-08-04T20:35:42Z
dc.date.available2024-08-04T20:35:42Z
dc.date.issued2011
dc.departmentİnönü Üniversitesien_US
dc.description.abstractWe aimed to evaluate plasma asymmetric dimethylarginine (ADMA) concentrations and its relation with insulin sensitivity/resistance indices in pregnant women with different degrees of carbohydrate intolerance. This study included a two step approach; 50 g glucose challenge test (GCT) followed by 100 g oral glucose tolerance test (OGTT) was used for diagnosis of carbohydrate intolerance within 24-28th weeks of gestation. Pregnant women with positive GCT but negative OGTT (AGCT group, n = 30) and gestational diabetics (GDM group, n = 58) were compared to healthy pregnant controls (n = 50). Plasma ADMA concentration and its relationship with glucose and insulin levels and insulin sensitivity/resistance indices (HOMA-IR, QUICKI, ISIOGTT) were evaluated. Both AGCT and GDM groups were found to have similarly higher plasma ADMA levels than control subjects (3.60 +/- 1.21; 4.00 +/- 1.70; 2.65 +/- 0.82 mu mol/l, respectively, P = 0.001). ADMA was significantly but slightly correlated with insulin sensitivity/resistance indices and moderately correlated with 2-h insulin level. The 2-h insulin value of the OGTT was the independent influencing constant for ADMA (R = 0.57, P = 0.0001). In conclusion, plasma asymmetric dimethylarginine level was higher in cases with abnormal glucose challenge test but normal OGTT as well as in gestational diabetics, compared to pregnant women with normal glucose tolerance. The elevated ADMA level in pregnant women with carbohydrate intolerance may possibly be due to elevated insulin level.en_US
dc.identifier.doi10.1007/s12020-011-9461-6
dc.identifier.endpage242en_US
dc.identifier.issn1355-008X
dc.identifier.issn1559-0100
dc.identifier.issue2en_US
dc.identifier.pmid21499819en_US
dc.identifier.scopus2-s2.0-84855187716en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage237en_US
dc.identifier.urihttps://doi.org/10.1007/s12020-011-9461-6
dc.identifier.urihttps://hdl.handle.net/11616/95525
dc.identifier.volume40en_US
dc.identifier.wosWOS:000296787800012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofEndocrineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAsymmetric dimethylarginine (ADMA)en_US
dc.subjectGestational diabetesen_US
dc.subjectAbnormal glucose challenge testen_US
dc.subjectInsulin resistanceen_US
dc.titleAsymmetric dimethylarginine level in hyperglycemic gestationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu